Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPE

Eyestem Research Pvt Ltd, a biotechnology company, has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate the clinical trial of its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE™ in India. The randomised, controlled phase 2 clinical trials will evaluate the safety and efficacy of Eyecyte-RPE™ in a larger group of subjects with moderate geographic atrophy (GA) and associated vision loss. Read the news on The Economic Times

The release as fetched from its publisher. eyestem.com ↗